Zilovertamab
- Generic Name
- Zilovertamab
- Drug Type
- Biotech
- CAS Number
- 2485779-13-1
- Unique Ingredient Identifier
- FEH7RQ7B3J
Merck's Zilovertamab Vedotin Shows Promise in Phase 2 DLBCL Trial, Phase 3 Initiated
• Merck's zilovertamab vedotin, combined with R-CHP, achieved a 100% complete response rate in previously untreated DLBCL patients in a Phase 2 trial.
• The 1.75 mg/kg dose of zilovertamab vedotin was established as the recommended dose for the Phase 3 trial based on efficacy and safety.
• A Phase 3 trial, waveLINE-010, has been initiated to evaluate zilovertamab vedotin plus R-CHP versus R-CHOP in previously untreated DLBCL patients.
• The waveLINE-010 trial aims to enroll 1,046 patients globally, with progression-free survival as the primary endpoint.
ONCT-534 Shows Promise in Metastatic Castration-Resistant Prostate Cancer
• Oncternal Therapeutics' ONCT-534 demonstrates potential in treating relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC).
• Twice-daily dosing of ONCT-534 was well-tolerated, with one patient experiencing a significant PSA reduction and target lesion decrease at a higher dose.
• Circulating tumor cell (CTC) analysis revealed promising effects on androgen receptor (AR)-regulated genes and AR nuclear translocation in some patients.
• The company is exploring strategic alternatives to further develop ONCT-534, including potential use in earlier lines of therapy for advanced prostate cancer.
Oncternal Therapeutics Halts B-Cell Lymphoma Trial and Explores Strategic Alternatives
• Oncternal Therapeutics discontinues its Phase 1/2 trial of ONCT-808, a CAR-T therapy targeting ROR1, for relapsed/refractory aggressive B-cell lymphoma due to strategic considerations.
• The decision follows promising early antitumor activity of ONCT-808, including complete metabolic responses, but also a patient death at the highest dose tested.
• Oncternal is also halting clinical trials for other pipeline candidates and reducing its workforce while exploring strategic options like asset sales or a merger.
• The company cites disappointing early results from the ONCT-534 prostate cancer trial and a challenging financing environment as key factors in the decision.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath